Business
Theralase(R) Announces Appointment of New Independent Director
TORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. (" Theralase® "...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Announces Appointment of New Independent DirectorTORONTO, ON / ACCESSWIRE / June 6, 2023 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco's Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one of the five most prominent cancer centers in the world. She holds a specialized executive master's degree in strategy and management from ESSEC Business School in Paris, a master's degree in international policy and health economics from the London School of Economics, a corporate governance certification from Columbia Business School and finance certification from Harvard Business School.Dr. Lbiati is an internationally trained medical doctor, who utilizes her extensive clinical and business background to assist biopharmaceutical organizations to achieve their strategic objectives through: systematic achievement of their value inflection milestones, partnering of their promising drug candidates with large international pharmaceutical companies and ultimately increasing shareholder value.Since 2022, Dr. Lbiati has been on the board of directors of Hepion Pharmaceuticals; a US public biotech (NASDAQ: HEPA) where she currently chairs the strategic planning committee and is member of the audit, science, nomination and governance committees.Prior to serving on the board of Hepion, Dr. Lbiati has been employed in executive and non-executive roles for: Cytovia Therapeutics, Steba Biotech and Immune Pharmaceuticals. She has been instrumental in helping these organizations: better define their corporate and business strategy, prioritize their pipeline, optimize technology platforms and effectively communicate their value proposition to international investors and partners, in order to secure funding, strategic partnerships and business development arrangements.Previous to these r...